Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelimumab + Famitinib + Chemotherapy in NSCLC with Meningeal Metastases
NCT06332300Phase 2Withdrawn
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, famitinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Planned start Feb 2024; status: withdrawn.
02
Drugs
adebrelimabfamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06332300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332300.